Time for an active antiviral therapy for hepatitis B: An update on the management of hepatitis B virus infection

References

• BarbonVMarzanoACarenziMTreatment with adefovir alone or in combination with lamivudine in chronic hepatitis B lamivudine-resistant patients: results after two yearsJ Hepatol200644S178
   Web of Science ®Google Scholar
• BzowejNChanHLYLaiCLA randomized trial of telbivudine (LdT) vs adefovir for HBeAg-positive chronic hepatitis B: final week 52 resultsHepatology200644563A
   Google Scholar
• ChaeHBHannHWBaseline HBV DNA level is the most important factor associated with viral breakthrough (BT) during lamivudine (LVD) therapy for chronic hepatitis B (CHB)Gastroenterology2006130A846
   Web of Science ®Google Scholar
• ChangT-TChaoY-CKaymakogluSEntecavir maintained virologic suppression through 3 years of treatment in antiviral naïve HBeAg(+) patientsHepatology2006a44229A
   Web of Science ®Google Scholar
• ChangT-TGishRGde ManRA comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med2006b35410011016525137
   PubMed Web of Science ®Google Scholar
• ChangTTGishRGHadziyannisSJA dose-ranging study of the efficacy and tolerability of entecavir in lamivudine-refractory chronic hepatitis B patientsGastroenterology2005129119820916230074
   PubMed Web of Science ®Google Scholar
• ChangTTLaiCLChienRNFour years of lamivudine treatment in Chinese patients with chronic hepatitis BJ Gastroenterol Hepatol20041912768215482535
   PubMed Web of Science ®Google Scholar
• ChenCJYangHISuJREVEAL–HBV GroupRisk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA levelJAMA2006295657316391218
   PubMed Web of Science ®Google Scholar
• ColonnoRJRoseRPokornowskiKFour year assessment of entecavir resistance in nucleoside-naïve and lamivudine refractory patientsJ Hepatol200746Suppl 1S294
   Web of Science ®Google Scholar
• ConjeevaramHSLokASManagement of chronic hepatitis BJ Hepatol200338Suppl 1S9010312591188
   PubMed Web of Science ®Google Scholar
• FungSKChaeHBFontanaRJVirologic response and resistance to adefovir in patients with chronic hepatitis BJ Hepatol2006442839016338024
   PubMed Web of Science ®Google Scholar
• GaneESafadiRXieQA randomized trial of telbivudine (LdT) versus lamivudine in lamivudine experienced patients-week 24 primary analysisHepatology200644Suppl 1564A
   Google Scholar
• HadziyannisSJTassopoulosNCChanTTLong-term adefovir dipivoxil treatment induces regression of liver fibrosis in patients with chronic hepatitis B: results after 5 years of therapyJ Hepatol2005a42754A
   Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJAdefovir Dipivoxil 438 study GroupLong-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis BN Engl J Med2005b35226738115987916
   PubMed Web of Science ®Google Scholar
• HannHWChaeHBDunnSTenofovir (TDF) has stronger antiviral effect than adefovir dipivoxil (ADV) against lamivudine (LVD) resistant hepatitis B virus (HBV)Gastroenterology2006130Suppl 2A846
   Google Scholar
• HannHWLFunkMLJRosenbergDMFactors associated with response to lamivudine: a retrosepctive study in a tertiary care clinic serving patients with chronic hepatitis BJ Gastroenterol and Hepatol2005204334015740489
   PubMed Web of Science ®Google Scholar
• KeeffeEBDieterichDTHanSHA treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an updateClin Gastroenterol Hepatol200649366216844425
   PubMed Web of Science ®Google Scholar
• LaiCLGaneEHsuCWTwo year results from the GLOBE trial in patients with chronic hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) Vs. LamivudineHepatology200644222A
   Google Scholar
• LaiCLLeungNTeoEKTelbivudine phase II investigator GroupA 1-year trial of telbivudine, lamivudine and the combination in patients with hepatitis Be Antigen-positive chronic hepatitis BGastroenterology20051295283616083710
   PubMed Web of Science ®Google Scholar
• LaiCLShouvalDLokASEntecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis BNew Engl J Med200635410112016525138
   PubMed Web of Science ®Google Scholar
• LamperticoPMarzanoALevreroMA multicenter Italian study of rescue adefovir dipivoxil therapy in lamivudine resistant patients: A 2 year analysis of 650 patientsJ Hepatol200644S51
   Web of Science ®Google Scholar
• LauGKCooksleyHRibieroRMRandomized double blind study comparing adefovir dipivoxil (ADV) plus emtricitabine (FTC) combination therapy versus ADV alone in HBeAg negative chronic hepatitis B: efficacy and mechanism of treatment responseHepatology2004401155A
   Google Scholar
• LauGKPiratvisuthYTLuoKXPeginterferon α-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis BN Engl J Med200535226829515987917
   PubMed Web of Science ®Google Scholar
• LeeHJSuhJIJangBIThe therapeutic effect of recombinant interferon α in chronic hepatitis B patientsKorean J of Gastroenterol19972977785
   Google Scholar
• LeeWMMedical progress: hepatitis B virus infectionN Engl J Med19973371733459392700
   PubMed Web of Science ®Google Scholar
• LeeYSSuhDJLimYSIncreased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapyHepatology20064313859116729316
   PubMed Web of Science ®Google Scholar
• LeungNPengCYSollanoJEntecavir results in higher HBV DNA reduction VS adefovir in chronically infected HBeAg(+) antiviral-naïve adults: 24 week results (E.A.R.L.Y. Study)Hepatology200644Suppl 1554A
   Google Scholar
• LiawYFLeungNGuanRAsian-Pacific consensus statement on the management of chronic hepatitis B: an updateJ Gastroenterol hepatol2003182394512603522
   PubMed Web of Science ®Google Scholar
• LiawYFLeungNGuanRAsian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 updateLiver international2005254728915910483
   PubMed Web of Science ®Google Scholar
• LiawYFLeungNWChangTTEffects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asian Hepatitis Lamivudine Study GroupGastroenterology20001191728010889166
   PubMed Web of Science ®Google Scholar
• LiawYFSungJJChowWCLamivudine for patients with chronic hepatitis B and advanced liver diseaseN Engl J Med200435115213115470215
   PubMed Web of Science ®Google Scholar
• LinCCWuJCChangTTLong-term evaluation of recombinant interferon alpha2b in the treatment of patients with hepatitis B e antigen-negative chronic hepatitis B in TaiwanJ Viral Hepatitis2001843846
   Web of Science ®Google Scholar
• LokASLaiCLLeungNLong-term safety of lamivudine treatment in patients with chronic hepatitis BGastroenterology200312517142214724824
   PubMed Web of Science ®Google Scholar
• LokASLaiCLWuPCLong-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infectionLancet19883322983022899719
   PubMed Web of Science ®Google Scholar
• LokASFMcMahonBJAASLD Practice guidelines: chronic hepatitis BHepatology20013412254111732013
   PubMed Web of Science ®Google Scholar
• LokASFMcMahonBJAASLD practice guidelines:chronic hepatitis B: update of recommendationHepatology2004398576114999707
   PubMed Web of Science ®Google Scholar
• MarcellinPChangTLimSIncreasing serologic, virologic and biochemical response over time to adefovir dipivoxil (ADV) 10 mg in HbeAg-positive chronic hepatitis B patientsJ Hepatol200542Suppl 231
   Google Scholar
• MarcellinPChangT-TLimSGAdefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BN Engl J Med20033488081612606735
   PubMed Web of Science ®Google Scholar
• MarcellinPLauGKKBoninoFPeginterferon α-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis BN Engl J Med200435112061715371578
   PubMed Web of Science ®Google Scholar
• MartinPHannHWWesterbergSInterferon-alpha2b therapy is efficacious in Asian-Americans with chronic hepatitis B infection: a prospective controlled trialDig Dis Sci19984387599580255
   PubMed Web of Science ®Google Scholar
• NowakMABonhoefferSHillAMViral dynamics in hepatitis B virus infectionProc Natl Acad Sci19969343984028633078
   PubMed Web of Science ®Google Scholar
• NunezMPerez-OlimedaMDiazBActivity of tenofovir on hepatitis B virus replicaion in HIV–co-infected patients failing or partially responding to lamivudineAIDS2002162352412441815
   PubMed Web of Science ®Google Scholar
• PapatheodoridisGVDimouEDimakopoulosKOutcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudineHepatology200542121915962291
   PubMed Web of Science ®Google Scholar
• PerrilloRPTherapy of hepatitis B-viral suppression or eradication?Hepatology200643Suppl 1S18393
   Google Scholar
• PerrilloRPLaiCLLiawYFPredictors of HBeAg loss after lamivudine treatment for chronic hepatitis BHepatology2002361869412085364
   PubMed Web of Science ®Google Scholar
• PerrilloRPSchiffERDavisGLA randomized, controlled trial of interferon α-2b alone and after prednisolone withdrawal for the treatment of chronic hepatitis B. The hepatitis interventional therapy groupNew Engl J Med19903232953012195346
   PubMed Web of Science ®Google Scholar
• PratiDTaioloEZanellaAUpdated definitions of healthy ranges for serum alanine aminotransferase levelsAnn Intern Med200213711012093239
   PubMed Web of Science ®Google Scholar
• RistigMBCrippinJAbergJATenofovir disoproxil fumarate therapy for chronic hepatitis B in human immunodeficiency virus/hepatitis B virus-coinfected individuals for whom interferon-alpha and lamivudine therapy have failedJ Infect Dis20021861844712447773
   PubMed Web of Science ®Google Scholar
• RosmawatiMLaiCLLaoLBaseline ALT level does not predict viral load reduction in response to entecavir therapyJ of Hepatol200338166 Abstr 574
   Web of Science ®Google Scholar
• RyuSHChungYHChoiMHLong term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective studyJ Hepatol2003396141912971973
   PubMed Web of Science ®Google Scholar
• SnowAThibaultVQiXCombination of adefovir (ADV) and lamivudine (LVD) prevented emergence of adefovir resistance mutations in chronic hepatitis B patients with lamivudine-resistant HBVGastroenterology2005128A745
   Web of Science ®Google Scholar
• SungJJYLaiYFZeuzemSA randomized, double-blind phase II study of lamivudine (LVD) compared o lamivudine plus adefovir dipivoxil (ADV) for treatment if naïve patients with chronic hepatitis B (CHB) week 52 analysisJ Hepatol200338Suppl 225
   Web of Science ®Google Scholar
• The EASL JuryEASL international consensus conference on hepatitis BJ Hepatol2003385334012663250
   PubMedGoogle Scholar
• Van BommelFWunscheTMaussSComparison of adefovir and tenofovir in the treatment of lamivudine resistant hepatitis B virus infectionHepatology2004401421515565615
   PubMed Web of Science ®Google Scholar
• Van BommelFWenscheTSchurmannDA comparison of adefovir and tenofovir in the treatment of lamivudine-resistant hepatitis B virus (HBV) infectionHepatology200338Suppl 1A246
   Google Scholar
• YuenMFSabionEHuiCKFactors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapyHepatology2001347859111584376
   PubMed Web of Science ®Google Scholar
• ZeuzemSde ManRAHonkoopPDynamics of hepatitis B virus infection in vivoJ of Hepatol19972743169314118
   PubMed Web of Science ®Google Scholar